We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Articles

Results 1 to 5 of 6
Most popular |Most recent


Revised Intellectual Property Enforcement Guidelines: Updates and Reminders from the Competition Bureau

Canada - May 2 2019 On March 13 2019, the Competition Bureau (the “Bureau”) released an updated version of its Intellectual Property Enforcement Guidelines ("IPEGs")...

Nicolas Charest, Chris Margison, Antonio Di Domenico, Huy A. Do.

IP Rights Holders: The Sky is Not Falling - Life Under Trump's NAFTA

Canada - April 11 2017 In the advent of President Trump's desire to revisit, renegotiate or perhaps, altogether repeal the NAFTA, one has to consider whether such an act...

Christelle Gedeon.

The Impact of CETA and Bill C-30 on Canada’s IP Landscape: Important Changes to Canadian Patent and Trademark Laws

Canada - December 5 2016 The Comprehensive Economic and Trade Agreement (CETA) was signed by Canada and the European Union (EU) on October 30, 2016. The next day, the Canadian...

Simon Hitchens.

Federal Court of Canada Rules in Favour of Fasken Martineau’s Client BRP, maker of the famous Ski-Doo snowmobiles

Canada - October 3 2016 In a lengthy judgment released on September 16, Federal Court Judge Yvan Roy convincingly dismissed a patent lawsuit brought against Bombardier...

Michael Shortt, Marek Nitoslawski, Joanie Lapalme.

Isolated human DNA molecules are patent eligible, cancer screening methods are not

Canada - August 17 2011 The United States Court of Appeals for the Federal Circuit on July 29, 2011 held in a split decision that isolated BRCA 12 DNA molecules patented and used by Myriad Genetics Inc. for diagnosing increased breast and ovarian cancer risk are patentable....

Serge Lapointe.